Logo image of INVO

INVO BIOSCIENCE INC (INVO) Stock Fundamental Analysis

NASDAQ:INVO - Nasdaq - US44984F4019 - Common Stock - Currency: USD

0.833  -0.03 (-2.91%)

After market: 0.825 -0.01 (-0.96%)

Fundamental Rating

2

Overall INVO gets a fundamental rating of 2 out of 10. We evaluated INVO against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of INVO have multiple concerns. INVO is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INVO had negative earnings in the past year.
INVO had a negative operating cash flow in the past year.
INVO had negative earnings in each of the past 5 years.
INVO had negative operating cash flow in 4 of the past 5 years.
INVO Yearly Net Income VS EBIT VS OCF VS FCFINVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of INVO (-39.30%) is worse than 61.70% of its industry peers.
INVO has a Return On Equity of -519.72%. This is amonst the worse of the industry: INVO underperforms 88.30% of its industry peers.
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROIC N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INVO Yearly ROA, ROE, ROICINVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

INVO's Gross Margin of 44.86% is on the low side compared to the rest of the industry. INVO is outperformed by 62.23% of its industry peers.
INVO's Gross Margin has declined in the last couple of years.
INVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
INVO Yearly Profit, Operating, Gross MarginsINVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

INVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INVO has more shares outstanding
Compared to 5 years ago, INVO has more shares outstanding
Compared to 1 year ago, INVO has an improved debt to assets ratio.
INVO Yearly Shares OutstandingINVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
INVO Yearly Total Debt VS Total AssetsINVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -5.70, we must say that INVO is in the distress zone and has some risk of bankruptcy.
INVO has a Altman-Z score of -5.70. This is in the lower half of the industry: INVO underperforms 70.74% of its industry peers.
A Debt/Equity ratio of 1.51 is on the high side and indicates that INVO has dependencies on debt financing.
With a Debt to Equity ratio value of 1.51, INVO is not doing good in the industry: 82.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Altman-Z -5.7
ROIC/WACCN/A
WACC7.27%
INVO Yearly LT Debt VS Equity VS FCFINVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

INVO has a Current Ratio of 0.30. This is a bad value and indicates that INVO is not financially healthy enough and could expect problems in meeting its short term obligations.
INVO's Current ratio of 0.30 is on the low side compared to the rest of the industry. INVO is outperformed by 94.68% of its industry peers.
A Quick Ratio of 0.27 indicates that INVO may have some problems paying its short term obligations.
The Quick ratio of INVO (0.27) is worse than 95.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.27
INVO Yearly Current Assets VS Current LiabilitesINVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

8

3. Growth

3.1 Past

INVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.65%, which is quite impressive.
INVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 384.42%.
INVO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.87% yearly.
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%

3.2 Future

INVO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
Based on estimates for the next years, INVO will show a very strong growth in Revenue. The Revenue will grow by 101.26% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INVO Yearly Revenue VS EstimatesINVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
INVO Yearly EPS VS EstimatesINVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INVO Price Earnings VS Forward Price EarningsINVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INVO Per share dataINVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as INVO's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

INVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVO BIOSCIENCE INC

NASDAQ:INVO (10/21/2024, 8:21:24 PM)

After market: 0.825 -0.01 (-0.96%)

0.833

-0.03 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners7.01%
Inst Owner Change-75.78%
Ins Owners9.11%
Ins Owner Change0%
Market Cap3.26M
Analysts43.33
Price Target20.4 (2348.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.47
BVpS0.35
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.86%
FCFM N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.84%
Cap/Sales 5.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.27
Altman-Z -5.7
F-Score4
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)577.96%
Cap/Depr(5y)746.78%
Cap/Sales(3y)8.92%
Cap/Sales(5y)8.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%
EBIT growth 1Y45.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.93%
OCF growth 3YN/A
OCF growth 5YN/A